Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).
D'Arcy
C A
CA
University of Washington, Seattle, USA.
Mannik
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000276:immunology; D000069283:Rituximab; D012377:Rodentia; D012713:Serum Sickness / Q000209:etiology* / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; D000069283:Rituximab